Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4

@inproceedings{Allen2015LargeScaleCS,
  title={Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4},
  author={Bryce K. Allen and Saurabh Mehta and Stewart W. J. Ember and Ernst Schonbrunn and Nagi George Ayad and Stephan C. Sch{\"u}rer},
  booktitle={Scientific reports},
  year={2015}
}
Inhibition of cancer-promoting kinases is an established therapeutic strategy for the treatment of many cancers, although resistance to kinase inhibitors is common. One way to overcome resistance is to target orthogonal cancer-promoting pathways. Bromo and Extra-Terminal (BET) domain proteins, which belong to the family of epigenetic readers, have recently emerged as promising therapeutic targets in multiple cancers. The development of multitarget drugs that inhibit kinase and BET proteins… CONTINUE READING
Highly Cited
This paper has 19 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 7 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Protein kinases--the major drug targets of the twenty-first century?

Nature reviews. Drug discovery • 2002
View 3 Excerpts
Highly Influenced